跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,551 条关于
“Fzd”
全部
1,551
临床试验
1,100
药物
404
机构
13
资讯
34
去年
Surrozen Secures Key Patent for Antibody-Based Wnt Pathway Modulators with Potential in Retinal Disease Treatment
去年
āshibio Licenses Vantictumab for Rare Bone Disease ADO2 in Strategic Pipeline Expansion
去年
Novel Frizzled 7 Antibody Shows Promise Against Wilms Tumor Through Wnt Pathway Disruption
上个月
Targeting the m6A Writer METTL3 Shows Neuroprotective Potential in Neuroinflammation
5个月前
Surrozen Advances Wnt-Based Retinal Therapeutics Pipeline, Plans IND Filing for SZN-8141 in Second Half of 2026
上个月
Surrozen Submits IND for SZN-8141, a Bifunctional Wnt Agonist/VEGF Antagonist for Diabetic Macular Edema
去年
Surrozen Reports Strong Q2 2025 Turnaround with $39.7M Net Income, Advances Retinal Disease Pipeline
上个月
Next-Generation 3D Cancer Models Reveal Clinically Relevant Gene Dependencies Missed by Traditional Cell Lines
3个月前
Cross-Species Single-Cell Atlas Reveals Conserved and Divergent Programs in Mammalian Fetal Ovarian Development
2年前
Passage Bio Advances in Clinical Trial for Genetic FTD Treatment
第 1 页,共 4 页
上一页
下一页